State Court: Teen Must Undergo Chemotherapy

The Connecticut Supreme Court ruled on Thursday that a 17 year old teen diagnosed with Hodgkin's lymphoma must undergo chemotherapy, contrary to her wishes and to the wishes of her mother.

The ruling of the court was unanimous.

The girl, called Cassandra C. in court papers and who is from Windsor Locks, Connecticut, wants to seek alternative therapies for her highly treatable cancer, and her mother says she does not want the toxic chemotherapy.

"She does not want the toxins," her mother told CBS. "She does not want people telling her what to do with her body."

The state Supreme Court heard testimony from doctors that the chances of the girl being cured of her disease through conventional therapy is between 80 and 85 percent, suggesting that she has been diagnosed as being stage II or stage III.

Previously, she had been removed from her mother's custody and put into the custody of the state in order to receive the curative therapy.

Her mother says she will continue to seek our alternative therapies for her daughter.

Source: WKBW
Photo by José Eugenio Gómez Rodríguez

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap